ifosfamide has been researched along with Leukemia, Myeloid, Acute in 16 studies
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "Primary mediastinal nonseminomatous germ cell tumors (NSGCT) have a worse prognosis than gonadal germ cell tumors (GCTs)." | 1.35 | Metastatic malignant teratoma arising from mediastinal nonseminomatous germ cell tumor: a case report. ( Carmichael, M; Collen, J; Wroblewski, T, 2008) |
| "One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13." | 1.33 | Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. ( Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Metzner, B; Schleicher, J; Schleucher, N; Wierecky, J, 2005) |
| "The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas." | 1.30 | Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
| "Six patients developed therapy-related acute myelogenous leukemia (t-AML)." | 1.30 | Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. ( Behnisch, W; Göbel, U; Hilgenfeld, E; Schneider, DT; Schwabe, D; Wessalowski, R; Zoubek, A, 1999) |
| " A critical question in comparing an experimental treatment to a standard is how much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa." | 1.30 | Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. ( Cheng, SC; Thall, PF, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kajita, N | 1 |
| Saito, Y | 1 |
| Makimoto, A | 1 |
| Miyahara, S | 1 |
| Yuza, Y | 1 |
| Kim, YD | 1 |
| Kim, KJ | 1 |
| Lee, YH | 1 |
| Scholz, M | 1 |
| Engert, A | 1 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 1 |
| Hasenclever, D | 1 |
| Loeffler, M | 1 |
| Bruserud, O | 1 |
| Reikvam, H | 1 |
| Kittang, AO | 1 |
| Ahmed, AB | 1 |
| Tvedt, TH | 1 |
| Sjo, M | 1 |
| Hatfield, KJ | 1 |
| Styczyński, J | 1 |
| Wysocki, M | 1 |
| Debski, R | 1 |
| Balwierz, W | 1 |
| Rokicka-Milewska, R | 1 |
| Matysiak, M | 1 |
| Balcerska, A | 1 |
| Kowalczyk, J | 1 |
| Wachowiak, J | 1 |
| Sońta-Jakimczyk, D | 1 |
| Chybicka, A | 1 |
| Wierecky, J | 1 |
| Kollmannsberger, C | 1 |
| Boehlke, I | 1 |
| Kuczyk, M | 1 |
| Schleicher, J | 1 |
| Schleucher, N | 1 |
| Metzner, B | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Bokemeyer, C | 1 |
| Takizawa, A | 1 |
| Miura, T | 1 |
| Fujinami, K | 1 |
| Osada, Y | 1 |
| Tanaka, M | 1 |
| Maruta, I | 1 |
| Abla, O | 1 |
| Dror, Y | 1 |
| Shago, M | 1 |
| Schäfer, HS | 1 |
| Becker, H | 1 |
| Schmitt-Gräff, A | 1 |
| Lübbert, M | 1 |
| Collen, J | 1 |
| Carmichael, M | 1 |
| Wroblewski, T | 1 |
| Norberg, B | 1 |
| Holm, J | 1 |
| Winqvist, E | 1 |
| Wahlin, A | 1 |
| Dunst, J | 1 |
| Ahrens, S | 1 |
| Paulussen, M | 1 |
| Rübe, C | 1 |
| Winkelmann, W | 1 |
| Zoubek, A | 2 |
| Harms, D | 1 |
| Jürgens, H | 1 |
| Schneider, DT | 1 |
| Hilgenfeld, E | 1 |
| Schwabe, D | 1 |
| Behnisch, W | 1 |
| Wessalowski, R | 1 |
| Göbel, U | 1 |
| Thall, PF | 1 |
| Cheng, SC | 1 |
| Büchner, T | 1 |
| Kamanabroo, D | 1 |
| Hiddemann, W | 1 |
| Urbanitz, D | 1 |
| Martens, AC | 1 |
| de Groot, CJ | 1 |
| Hagenbeek, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifosfamide and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
15 other studies available for ifosfamide and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Fatal Outco | 2020 |
Secondary leukemia in a child conceived using in vitro fertilization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Child, | 2008 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Glucose; Humans; Ifosfamide; In Vitro | 2002 |
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Etopo | 2005 |
[A case of therapy-related leukemia/myelodysplastic syndrome following treatment of refractory testicular germ cell tumor].
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Ci | 2005 |
Translocation (X;10) in a child with therapy-related acute myeloid leukemia following chemotherapy for Ewing's Sarcoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Huma | 2007 |
Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; CA-19-9 Antig | 2008 |
Metastatic malignant teratoma arising from mediastinal nonseminomatous germ cell tumor: a case report.
Topics: Adult; Dacarbazine; Doxorubicin; Fatal Outcome; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Male; | 2008 |
Treatment of advanced bone marrow neoplasms with ifosfamide combinations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphami | 1984 |
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |
Acute myelogenous leukemia after treatment for malignant germ cell tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cisp | 1999 |
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia, | 1999 |
[Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine].
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Ifosfamide; Leukemia, Myeloid, A | 1978 |
Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclophosphamide; Disease Models, Animal; Dose-Response R | 1991 |